Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs TORM plc — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while TORM plc trades at $39.7 (market cap $4.21B). The key difference: TORM plc is far larger — about 4.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and TORM plc pays a 10.75% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and TORM plc for 23 Days on average.
| MRVI | TRMD | |
|---|---|---|
Market Cap | $972.90M | $4.21B |
Volume | 4,325,710 | 1,504,714 |
Sector | Health | Industrials |
52-Week High | $9.00 | $41.11 |
52-Week Low | $2.83 | $19.39 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $1.08B | $4.92B |
Dividend Yield | — | 10.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
TRMD trades at $41.11, up 0.46% with strong bullish technical signals from moving averages. The company shows robust fundamentals with a P/E of 6.76, net income margin of 35.52%, and ROE of 26.84%. Recent earnings show mixed results with Q2 2026 missing expectations but strong year-over-year growth projected. Analyst consensus is unanimously bullish with 100% buy ratings. The stock faces headwinds from declining spot rates as noted in recent analysis.
Outlook remains positive based on strong profitability and valuation metrics, though near-term pressure from freight rate declines presents risk. The dividend yield of approximately 5.8% provides income support. Institutional accumulation and solid cash flow generation support the bullish case, but investors should monitor tanker rate trends closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
